Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib in resectable malignant pleural mesothelioma
NCT02004028Phase 2Terminated
- Sponsor
- Verastem Oncology
- Start
- Dec 2013
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of defactinib in malignant pleural mesothelioma (MPM), sponsored by Verastem Oncology. Started Dec 2013; status: terminated.
02
Drugs
defactinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT02004028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02004028.